Pfizer Earnings Preview
Pfizer, Inc. (PFE)
Background: Pfizer Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and sale of medicines for people and animals worldwide.
Pfizer is forecast to report WEAK third-quarter earnings before the market opens on October 28, 2014.
The consensus estimate is currently 55 cents a share, falling 3 cents (5.2%) from 58 cents during the same period last year.
Analysts are estimating as low as 53 cents per share, up to the most optimistic estimate of 58 cents per share.
Investors are receiving $1.04 in dividends for a yield of 3.7%. In the last five years, the average yield was 3.60%.
Analysts as a whole like this company. Currently, Pfizer has 13 buy recommendations out of 21 analysts covering the company, along with 6 holds, and 2 recommend selling. Investors haven't made progress this year. Shares in the company have fallen 8% from a year ago. The average analyst target price for Pfizer is $34.13.